|
|||||
|
|

Health and wellness products company Herbalife (NYSE:HLF) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.7% year on year to $1.27 billion. The company expects next quarter’s revenue to be around $1.25 billion, close to analysts’ estimates. Its non-GAAP profit of $0.50 per share was 8.4% above analysts’ consensus estimates.
Is now the time to buy HLF? Find out in our full research report (it’s free for active Edge members).
Herbalife’s third quarter saw sales growth return in North America and globally, marking a notable shift after several quarters of flat or declining performance in key markets. Management credited this to disciplined execution and renewed distributor engagement, particularly in North America, where new distributor growth reached 17%. CEO Stephan Gratziani cited the role of product launches like Multiburn and ongoing programs such as the Diamond Development Mastermind in energizing distributors, stating, “This is a significant milestone…a reflection of nearly two years of disciplined execution and foundational work across every level of the business.”
Looking forward, Herbalife’s management expects continued momentum from technology-driven initiatives, including the commercial release of its Pro2col personalized health platform and further expansion of its HL/Skin line. The company plans to introduce at-home biomarker testing and personalized nutritional supplements, with beta access targeted for U.S. distributors in the coming quarters. CFO John DeSimone emphasized the company’s intent to leverage both digital tools and its direct sales network, noting, “We believe there is a big place in the future for subscription revenue,” indicating a potential shift in revenue streams as new offerings mature.
Management pointed to North America’s distributor-led recovery, the launch of new wellness products, and the company’s increased use of technology as primary drivers of the quarter’s performance.
Herbalife’s outlook is anchored by investments in digital engagement, new product launches, and the scaling of personalized health offerings, though margin pressures and regional demand shifts remain key considerations.
In the coming quarters, our team will be watching (1) the commercial rollout and user adoption rates for the Pro2col personalized health platform, (2) the expansion and performance of new product lines such as HL/Skin and Multiburn across additional markets, and (3) the company’s ability to sustain distributor engagement and leadership development initiatives. Execution on margin management and the transition toward subscription-based business models will also be closely monitored as potential indicators of sustainable growth.
Herbalife currently trades at $8.72, up from $8.30 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Nov-06 | |
| Nov-06 | |
| Nov-06 | |
| Nov-05 | |
| Nov-05 | |
| Nov-05 | |
| Nov-04 | |
| Nov-03 | |
| Oct-30 | |
| Oct-27 | |
| Oct-13 | |
| Oct-08 | |
| Oct-06 | |
| Oct-02 | |
| Oct-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite